|
1
|
Niccoli G, Kharbanda RK, Crea F and
Banning AP: No-reflow: Again prevention is better than treatment.
Eur Heart J. 31:2449–2455. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang D, Wang L, Du J, et al: Effect of
intracoronary tirofiban combined with nitroprusside injection
through thrombus aspiration catheter during primary percutaneous
coronary intervention on acute anterior myocardial infarction
patients with heavy thrombosis burden. Zhonghua Xin Xue Guan Bing
Za Zhi. 42:25–30. 2014.[(In Chinese)]. PubMed/NCBI
|
|
3
|
Li MW, Zhao XM, Rao LX, et al: The
clinical efficacy and safety of fondaparinux combined with
tirofiban hydrochloride in patients with acute coronary syndrome
undergoing complex percutaneous coronary intervention. Zhonghua Nei
Ke Za Zhi. 52:1037–1040. 2013.[(In Chinese)]. PubMed/NCBI
|
|
4
|
Ren LH, Peng JJ, Ye HM, Wang ZY and Chen
C: High-dose tirofiban in patients with acute ST-segment elevation
myocardial infarction undergoing primary percutaneous coronary
interventio. Zhonghua Yi Xue Za Zhi. 92:1981–1983. 2012.[(In
Chinese)]. PubMed/NCBI
|
|
5
|
Li X, Lei Y and Zheng Q: Myocardial
infarction caused by coronary artery dissection due to blunt
injury: Is thromboaspiration an appropriate treatment. Hellenic J
Cardiol. 55:61–64. 2014.PubMed/NCBI
|
|
6
|
He WK, Li MY, Xing XW and Lu DF: The
effects of different ways of tirofiban injection on prognosis of
the patients with AIM treated with PIC. Shi Yong Yi Xue Za Zhi.
28:2936–2939. 2012.
|
|
7
|
Tong ZC, Li Q, Chen M, et al: Efficacy
comparison of combined intracoronary administration of high-dose
adenosine and tirofiban versus intracoronary tirofiban during
primary percutaneous coronary intervention in patients with acute
myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi.
41:839–844. 2013.[(In Chinese)]. PubMed/NCBI
|
|
8
|
Zhang Y, Gao CY, Zhu ZY, et al: Efficacy
and safety of tirofiban use after successful percutaneous coronary
intervention for patients with moderate to high risk non-ST segment
elevation acute coronary syndromes. Zhonghua Xin Xue Guan Bing Za
Zhi. 41:731–735. 2013.[(In Chinese)]. PubMed/NCBI
|
|
9
|
Gibson CM, Karha J, Giugliano RP, et al:
INTEGRITI Study Group: Association of the timing of ST-segment
resolution with TIMI myocardial perfusion grade in acute myocardial
infarction. Am Heart J. 147:847–852. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qin T, Xie L and Chen MH: Meta-analysis of
randomized controlled trials on the efficacy and safety of
intracoronary administration of tirofiban for no-reflow phenomenon.
BMC Cardiovasc Disord. 13:682013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li W, Fu X, Xue H, et al: Efficacy and
safety of standard-dose versus half-dose tirofiban in patients with
non-ST elevation acute coronary syndromes undergoing early
percutaneous coronary intervention. Cardiovasc Ther. 31:210–214.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao YJ, Fu XH, Ma XX, et al:
Intracoronary fixed dose of nitroprusside via thrombus aspiration
catheter for the prevention of the no-reflow phenomenon following
primary percutaneous coronary intervention in acute myocardial
infarction. Exp Ther Med. 6:479–484. 2013.PubMed/NCBI
|
|
13
|
Balghith M, Al-Ghamdi A, Zain el H and
Al-Saileek A: Intracoronary Reopro During Percutaneous Coronary
Intervention In Acute And Stable Patient Can Influence Stent
Thrombosis Formation (IRPASST) study. Heart Views. 14:62–67. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tas MH, Simsek Z, Ayan A, et al: Effects
of tirofiban maintenance duration on myocardial perfusion defect
severity in anterior myocardial infarction. Adv Ther. 30:834–844.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hong TT, Huang J, Driscoll E and Lucchesi
BR: The antithrombotic effect of melagatran in combination with
clopidogrel and/or aspirin (carotid artery primary thrombosis
study). J Cardiovasc Pharmacol. 46:526–533. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Y, Gao C, Liu H, et al: Routine
early versus deferred provisional tirofiban treatment in patients
with acute coronary syndrome undergoing percutaneous coronary
intervention. Clin Exp Pharmacol Physiol. 40:289–294. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deshpande NV, Pratiti R, Admane P,
Mukherjee D and Mardikar HM: Safety and efficacy of bivalirudin
with glycoprotein IIb/IIIa for high-risk percutaneous coronary
intervention. Indian Heart J. 64:444–448. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Balghith MA: High bolus tirofiban vs
abciximab in acute STEMI patients undergoing primary PCI - The
Tamip study. Heart Views. 13:85–90. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu X, Dong P, Xing S, et al: Clinical
evaluation of thrombus aspiration combined with tirofiban in
patients with acute myocardial infarction with elective
percutaneous coronary intervention. J Int Med Res. 41:1532–1540.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jia Z, Guo M, Zhang YQ, Liang HQ and Song
Y: Short-term effect of upstream administration in comparison to
deferred injection of tirofiban on patients with acute ST-segment
elevation myocardial infarction undergoing primary percutaneous
coronary intervention. J Interv Cardiol. 26:332–329. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Q, Qiu JP, Zhang RY, et al: Improved
outcomes from transradial over transfemoral access in primary
percutaneous coronary intervention for patients with acute
ST-segment elevation myocardial infarction and upstream use of
tirofiban. Chin Med J (Engl). 126:1063–1068. 2013.PubMed/NCBI
|
